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The lactate dehydrogenase-A (LDH-A) enzyme cata-
lyzes the interconversion of pyruvate and lactate, is
upregulated in human cancers, and is associated
with aggressive tumor outcomes. Here we use an
inducible murine model and demonstrate that inacti-
vation of LDH-A in mouse models of NSCLC driven
by oncogenic K-RAS or EGFR leads to decreased
tumorigenesis and disease regression in established
tumors. We also show that abrogation of LDH-A re-
sults in reprogramming of pyruvate metabolism,
with decreased lactic fermentation in vitro, in vivo,
and ex vivo. This was accompanied by reactivation
of mitochondrial function in vitro, but not in vivo or
ex vivo. Finally, using a specific small molecule
LDH-A inhibitor, we demonstrated that LDH-A is
essential for cancer-initiating cell survival and prolif-
eration. Thus, LDH-A can be a viable therapeutic
target for NSCLC, including cancer stem cell-depen-
dent drug-resistant tumors.
INTRODUCTION
The enhancement of aerobic glycolysis, i.e., the Warburg effect
(lactate production in the presence of adequate oxygen) (War-
burg, 1930, 1956), not only provides cancer cells with a survival
advantage but also links it to invasive ability (Gatenby andGillies,
2004). This effect has been seen in different types of tumors, and
the concomitant increase in glucose uptake is exploited clinicallyCfor detection of tumors by 2-fluorodeoxyglucose-based positron
emission tomography (FDG-PET) (Gillies, 2001; Hsu and Saba-
tini, 2008).
Non-small cell lung cancer (NSCLC) is highly glycolytic, ac-
counts for >85% of all lung cancers (Gazdar and Minna, 1999),
and is the leading cause of cancer deaths. Mutations at codon
12, which constitute the majority of K-RAS mutations (Forbes
et al., 2006), promote fermentative glycolysis in NSCLC (Vizan
et al., 2005). Enhanced fermentative glycolysis in a hypoxic tu-
mor microenvironment results in increased acid production
(Ebert et al., 1996), which in turn lowers extracellular pH and
has been linked to the metastatic ability of cancer cells (Fischer
et al., 2007; Walenta et al., 1997).
K-RAS mutations have been frequently reported in NSCLC,
particularly in adenocarcinoma (Riely et al., 2009). Mutations in
EGFR are also common in NSC adenocarcinomas, and are
generally exclusive with K-RAS mutations. Somatic activating
mutations in EGFR produce a constitutively active tyrosine-
kinase (L858R), and tumors bearing these mutations respond
to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erloti-
nib (Amann et al., 2005; Kobayashi et al., 2005). Clinically,
despite the dramatic responses to such inhibitors, most patients
relapse, owing to acquiring the resistance mutations (T790M,
and L747S) (Costa et al., 2007). Any potential therapeutic oppor-
tunity that can address highly glycolytic NSCLC will have a sig-
nificant clinical impact.
Tumor-initiating cells (TICs) or cancer stem cells (CSCs)
comprise a small population of tumor-forming, self-renewing
cancer cells within a tumor and are associated with aggressive
disease and poor prognosis (Ailles and Weissman, 2007). It
has been suggested that CSCs cluster in hypoxic niches, rely
on fermentative glycolysis, and have decreased mitochondrial
respiration similar to progenitor cells during normal developmentell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 795
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indispensable for progenitor proliferation and biosynthesis (Aga-
thocleous et al., 2012).
Targeting tumor metabolism via antiglycolytic therapies may
offer a therapeutic opportunity, as it represents a key
converging step for multiple deregulated signaling pathways in
cancer cells. The lactate dehydrogenase-A gene (LDH-A), a
target for HIF-1a and MYC, is of particular interest because it
catalyzes the NADH-dependent reduction of pyruvate to
lactate, a step essential for regenerating the NAD+, which is
needed for maintaining glycolysis and other metabolic activities.
Enhanced expression of LDH-A has been associated with evo-
lution of aggressive and metastatic cancers in a variety of tumor
types (Koukourakis et al., 2005). Since therapies to address
highly glycolytic NSCLC tumors are limited, development of
LDH-A inhibitors may have a significant impact on this patient
population.
Here, we detail the generation of a tamoxifen-regulated cre-
recombinase conditional mouse model of LDH-A deletion
(Cretm-LDH-Afl/fl). To investigate the role of LDH-A in NSCLC,
we have used Ccsp-rtTA/(tetO)7-K-RAS4bG12D bitransgenic
mice (Fisher et al., 2001) and Ccsp-rtTA/(tetO)-EGFR L858R-
T790M (Regales et al., 2007) to generate Cretm-LDH-Afl/fl;
Ccsp-rtTA/(tetO)7-K-RAS4bG12D andCretm-LDH-Afl/fl;Ccsp-rtTA/
(tetO)-EGFR-L858R-T790M, respectively. TheseCretm-LDH-Afl/fl;
Ccsp-rtTA/(tetO)7-K-RAS4bG12D andCretm-LDH-Afl/fl;Ccsp-rtTA/
(tetO)-EGFR-L858R-T790M mice serve as preclinical models in
which tumors canbe initiated in lung tissueby induction ofmutant
K-RAS orEGFR-L858R-T790Mbydoxycycline, while LDH-A can
be removed in all adult tissues including the lung. This model
has enabled us to test the impact of LDH-A inhibition in estab-
lished tumors. We show that LDH-A expression is required for
the development of K-RAS-dependent tumors. Importantly, we
also show that blockade of LDH-A is therapeutically efficacious
in establishedmutatedK-RAS andEGFR-L858R-T790M-depen-
dent tumors. Indeed, established tumors regress with reduced
LDH-A.
We have also examined the impact of LDH-A suppression on
cancer metabolism in vitro. We have previously shown that
LDH-A abrogation leads to increased production of reactive
oxygen species (ROS) and apoptosis in cancer cells, likely the
result of increased respiration (Xie et al., 2009). Here, using sta-
ble isotope tracers coupled with metabolomic analysis (stable
isotope-resolved metabolomics or SIRM), we demonstrated
that LDH-A suppression in cultured cancer cells enhances the
Krebs cycle, oxygen consumption, and mitochondrial ROS pro-
duction (Seth et al., 2011).Moreover, using SIRM,we have inves-
tigated the metabolic effect of LDH-A attenuation in vivo in our
newmousemodel and ex vivo in freshly prepared humanNSCLC
tissue slices. Similar to the in vitro result, glycolytic production of
13C-lactate from 13C6-glucose was attenuated in LDH-A sup-
pressed mouse lung tumors and LDH-A inhibitor-treated human
tumor slices, but the Krebs cycle activity was not activated either
in vivo or ex vivo.
It has been speculated that CSCs exhibit the Warburg
phenotype and may benefit from antiglycolytic therapies. We
demonstrate that oncogenic K-RAS-expressing CSCs are highly
susceptible to loss of LDH-A expression. We also validate these
findings using an LDH-A-specific inhibitor.796 Cell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc.RESULTS
Generation and Characterization of Cretm-LDH-Afl/fl
Mice
Since LDH-A deletion is embryonic lethal (data not shown), we
have generated conditional LDH-A transgenic mice controlled
by tamoxifen-regulated cre-recombinase (Cretm) for inducible
inactivation the LDH-A gene. The schematic (see Figures S1A–
S1H available online) describes LDH-A gene inactivation.
Loss of LDH-A Results in Hemolytic Anemia
Within 6 weeks of tamoxifen treatment, Cretm-LDH-Afl/fl mice,
but not LDH-Afl/fl, developed severe but nonlethal hemolytic
anemia, as evidenced by reduced numbers of red blood cells
(RBCs) in the peripheral blood (Figure S2A). Blood smears
stained with May-Grunwald-Giemsa-marked polychromasia,
indicating release of early RBCs from the marrow in response
to peripheral hemolysis (Figure S2C). The spleens of transgenic
animals were greatly enlarged due to marked expansion of red
pulp from hyperplastic erythroid precursors, and increased he-
mosiderin deposits characteristic of RBC phagocytosis were
evident (Figures S2B and S2C). Flow cytometry analysis further
confirmed the expansion of CD71+Ter119+ immature erythro-
blasts in the bone marrow, spleen, and peripheral blood of
Cretm-LDH-Afl/fl animals (Figure S2D). Notably, tamoxifen-
treated Cretm-LDH-Afl/+ animals developed a partial phenotype
(Figures S2A–S2D), as evident in both morphologic and flow cy-
tometric analyses, demonstrating that LDH-A is haplo-insuffi-
cient with respect to erythropoiesis.
Reduction in LDH-AProtein Levels Results in Decreased
Tumorigenesis in a K-RAS-Driven NSCLC Model
In order to generatemice that have all the alleles, Cretm-LDH-Afl/fl
mice were mated with Ccsp-rtTA/(tetO)7-K-RAS4bG12D (here-
after referred to as K-RAS) to generate Cretm-LDH-Afl/fl;Ccsp-
rtTA/(tetO)7-K-RAS4bG12D (homozygous for LDH-A, hereafter
referred as Cretm-LDH-Afl/fl;K-RAS) or Cretm-LDH-Afl/+;Ccsp-
rtTA/(tetO)7-K-RAS4bG12D (heterozygous for LDH-A, hereafter
referred to as Cretm-LDH-Afl/+;K-RAS) mice. In these mice, addi-
tion of doxycycline turns on the oncogenic K-RAS expression in
a lung-specific manner, and intraperitoneal injection of tamox-
ifen turns off LDH-A expression in all the adult organs. Similarly,
control LDH-Afl/fl-Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice lacking
the Cretm gene were generated (hereafter referred to as LDH-
Afl/fl;K-RAS).
To assess the role of LDH-A in the initiation of oncogenic
K-RAS tumors, we took 5-week-old Cretm-LDH-Afl/fl;K-RAS
andCretm-LDH-Afl/+;K-RASmice and initiated doxycycline treat-
ment for an additional 2 weeks to activate mutant K-RAS (Fig-
ure 1A). Following that, we initiated intraperitoneal tamoxifen
injection (10 mg ml1) in corn oil every day for 5 days. We vali-
dated success of cre-recombination by RT-PCR analysis by as-
sessing loss of exon 2 and sequencing the truncated LDH-A pro-
tein (Figures S1I–S1K). The control was the identical experiment
in which we injected corn oil as a vehicle with the same schedule.
As shown in Figure 1, reduced LDH-A expression resulted in
significant reduction in tumor area, suggesting that fermentative
glycolysis is a key bioenergetic pathway in oncogenic K-RAS-
driven tumors. The data also show that deletion of just one allele
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(Figures 1B and 1C). The decreased expression of LDH-A in
lung tumors was verified by western blot analysis. No changes
were detected in LDH-B expression when LDH-A gene was
deleted (Figures 1D and 1E). To validate the effects of LDH-A
abrogation in vivo, a single Cretm-LDH-Afl/fl;K-RAS mouse was
imaged using proton MRI (Figure 1F) and hyperpolarized 13C
MRSI (Figures 3F–3H) before and after inactivation of LDH-A
by tamoxifen administration. As shown (Figures 1F–1H), the solid
lesions exhibited reductions in the lactate-to-pyruvate ratio
levels in the tumor just 10 days after final tamoxifen treatment.
For the larger lesion, the ratio fell from 0.47 ± 0.01 to 0.37 ±
0.05, while for the smaller lesion the ratio fell from 0.50 ± 0.04
to 0.31 ± 0.10. The spectra illustrating this reduction in the
smaller lesion are shown (Figure 1H). Furthermore, abrogation
of LDH-A in tumors led to decreased lactate levels, a decreased
NAD+/NADH ratio, and increased pyruvate and isocitrate levels
(Figure 1I), all consistent with increased mitochondrial oxidation.
Cleaved caspase-3 immunohistochemical analysis (IHC)
showed increased apoptosis in K-RAS-driven tumors that have
reduced LDH-A expression (Figure 1J). We also observed
reduced disease in lungs of tamoxifen-treated Cretm-LDH-
Afl/fl;K-RAS mice using high-resolution axial CT images of lung/
chest (Figure 1K).
Reduction in LDH-A Protein Levels Results in
Regression of Established Tumors in a K-RAS-Driven
NSCLC Model
To assess whether inhibition of LDH-A in an established tumor
can impact tumor progression, 5-week-old Cretm-LDH-Afl/fl;
K-RAS and Cretm-LDH-Afl/+;K-RAS mice were maintained on a
doxycycline diet for an additional 9 weeks. Following that, we
initiated intraperitoneal tamoxifen injections (10 mg ml1) in
corn oil every day for 5 days (Figure 2A).
Deletion of just one allele of LDH-A results in substantial tumor
reduction in this GEMmodel (Figures 2B and 2C). The decreased
expression of LDH-A in lung tumors was verified by western blot
analysis, and no changes were detected in LDH-B expression
when LDH-A gene was deleted (Figure 2D). The degree of
LDH-A attenuation is consistent with the homozygous and het-
erozygous knockdown. Furthermore, to quantify the response
of LDH-A ablation on tumor growth in Cretm-LDH-Afl/fl;K-RAS
in real time, we scanned Cretm-LDH-Afl/fl;K-RAS and LDH-
Afl/fl;K-RAS mice before and after tamoxifen treatment. We
observed marked regression in tumor growth 10 day after last
tamoxifen treatment as measured by coronal and transverse
section CT imaging (Figures 2F and 2G) and representative volu-
metric assessment of the total lung volume (Movie S1). These
results suggest that targeting LDH-A in a K-RAS-driven tumor
results in tumor regression and that targeting LDH-A in lung can-
cer might have therapeutic efficacy.
Reduction in LDH-AProtein Levels Results in Decreased
Tumorigenesis andRegression of EstablishedTumors in
EGFR-Resistant NSCLC Model
Aggressive lung tumors, such as those that are resistant to
EGFR inhibitors, might be amenable to therapeutic targeting
via LDH-A. To test this hypothesis, we generated a Cretm-
LDH-Afl/fl;Ccsp-rtTA/(tetO)-EGFR-L858R-T790M mouse modelC(referred as Cretm-LDH-Afl/fl;EGFR-T790M). These mice ex-
press EGFR mutation L858R as well as T790M mutation.
Similar to the K-RAS model, the EGFR-L858R-T790M expres-
sion can be activated in lung epithelial cells by doxycycline,
and LDH-A expression (whole body) can be modulated by
administering tamoxifen.
Five-week-oldCretm-LDH-Afl/fl;EGFR-T790M,Cretm-LDH-Afl/+;
EGFR-T790M, and LDH-Afl/fl;EGFR-T790M mice were main-
tained on a doxycycline diet for an additional 8 weeks, as shown
(Figure 3A). The responseofLDH-A suppression on tumor growth
in Cretm-LDH-Afl/+;EGFR-T790M was quantified in real time, and
we performed CT imaging analysis of Cretm-LDH-Afl/fl;EGFR-
T790M, Cretm-LDH-Afl/+;EGFR-T790M, and LDH-Afl/fl;EGFR-
T790M mice before and after tamoxifen treatment. We show
marked regression in tumor growth 20 days after the last tamox-
ifen treatment asmeasuredbycoronal and transverse section im-
agingbyCTscan (Figures 3Band3C) and volumetric assessment
of total lung volume. The graphical representation of volumetric
analysis is shown as net change in lung volume (Figure 3E). The
decreased expression of LDH-A in lung tumors was verified by
western blot analysis (Figure 3D). The data also show that dele-
tion of LDH-A results in substantial tumor reduction similar to
the K-RAS model. These results suggest that targeting LDH-A
in EGFRT-790M-driven tumors results in tumor regression. How-
ever, unlike the K-RAS tumors where heterozygous ablation of
LDH-Awas therapeutically efficacious, the EGFR-T790M-driven
tumors showed a smaller decrease, and one out of four tumors
showed increase in tumor growth in the fourth week of
monitoring.
Genetic and Pharmacologic Targeting of LDH-A
Suppress Cancer Stem Cell Function
We next asked whether CSCs are susceptible to reduction in
LDH-A levels. To investigate the in vivo role of LDH-A in tumor-
initiating capacity in oncogenic K-RAS tumors, we isolated
tumor cells from Cretm-LDH-Afl/fl;K-RAS or Cretm-LDH-Afl/fl;
K-RAS mice that were treated with tamoxifen. As shown in Fig-
ure 4, when introduced via tail vein in C57BL6 mice, tumor cells
with diminished LDH-A expression colonized the lung at a signif-
icantly decreased rate compared to tumor cells that have normal
levels of LDH-A expression (Figure 4B). Injection of A549 cells
expressing control or LDH-A shRNA in tail vein metastasis assay
in athymic mice gave similar results (Figure 4A). Reduction in
LDH-A expression in both A549 and Cretm-LDH-Afl/fl;K-RAS
was confirmed by western immunoblotting (Figures 4C and
4D). These findings are consistent with an in vitro matrigel inva-
sion assay with NSCLC A549 cells expressing LDH-A shRNA
(Figure 4C). Collectively these data suggest that blockade of
fermentative glycolysis diminishes tumor-initiating capacity,
possibly via blocking CSCs.
Next, to assess the role of LDH-A on CSCs in vitro, we next
downregulated LDH-A by shRNA in A549 cells and seeded
them in a tumorsphere formation assay. As shown (Figures 4E
and 4F), downregulation of LDH-A expression significantly
reduced the ability of A549 cells to form tumorspheres. To
assess whether these results can be recapitulated in another
oncogenic RAS cell line, we utilized a well-established RAS-
induced mammary tumorigenesis system (HMLER) that has
been used for CSCs analysis (Al-Hajj et al., 2003; Mani et al.,ell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 797
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results in a significant decrease in CSCs as assessed by tumor-
sphere assay and by the expression of CD24/44 markers (Fig-
ure 4G). We further showed that tumor cells isolated from lungs
of tamoxifen-treated Cretm-LDH-Afl/fl;K-RASmice formed signif-
icantly fewer tumorspheres than lung cells from LDH-Afl/fl;K-RAS
mice, suggesting that LDH-A abrogation impacts CSCs in vivo
(Figures 4H and 4I).
To validate these findings with LDH-A suppression, we used
a specific inhibitor of LDH-A (Compound 1) developed at
GlaxoSmithKline (Figure 5A). Compound 1 inhibited recombinant
humanLDH-Aenzymewith anKi = 4.8±1.1nMandshowed10-
fold selectivity over LDH-B (Figure 5B) and results in apoptosis
(Billiard et al., 2013). Compound 1 decreased cellular lactate pro-
duction in HepG2 hepatocellular carcinoma cells with an EC50 =
588 ± 200 nM (Figure 5C), increased ROS production (Figure 5D),
decreased extracellular acidification rate (Figure 5E), and
increased oxygen consumption rate (OCR) (Figure 5F).
We also found that downregulation of LDH-A activity by Com-
pound 1 reduced the ability of A549 cells to form tumorspheres
(Figures 5G and 5H) and decreased the number of CD24/44-pos-
itive cells in HMLER system (Figure 5I) and in stem cells isolated
from HMLER (Figure S5A). To investigate whether the observed
decrease in CSCs is specific, we cultured HMLER cells with
10 mM Compound 1 for 48 hr before replating them in the pres-
ence or absence of Compound 1. Figure 5J shows that CD24/
44 positive cells reappear after withdrawal of the inhibitor, sug-
gesting that Compound 1 affects CSC phenotype. Finally, treat-
ment with Compound 1 significantly reduced the number of
tumorspheres generated by tumor cells isolated from lungs of
Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice (Figures 5K and 5L).
To investigate the specificity of LDH-A inhibitor targeting stem
versus nonstem, we performed proliferation assay, which
showed that the LDH-A inhibitor does not exclusively target
stem cells, but the impact on stem cells is significant compared
to nonstem cells (Figure 5B). To extend our results, we also used
another previously published stem cell system, i.e., MCF10A
cells expressing shPTEN or overexpressing PIK3CA (Hanai
et al., 2013), to demonstrate that an LDH-A inhibitor reduced
the stem cell population as assessed by the tumorsphere assay
(Figure 6C).Figure 1. LDH-A Expression Is Required for Initiation of Oncogenic K-
(A) Schematic representation of an experiment in which LDH-A knockdown was
(B) Tumor areas of Cretm-LDH-Afl/fl;K-RAS mice treated with tamoxifen (n = 7) or
(C) Tumor areas of Cretm-LDH-Afl/fl;K-RAS (n = 3), Cretm-LDH-Afl/+;K-RAS (n = 5) a
B and C are represented as mean ± SD, *p < 0.05, **p < 0.01 as calculated by tw
(D) Representative western blot analysis of tumor (along with nonmalignant cells
RAS mice.
(E) Representative western blot analysis of tumor (along with nonmalignant cells) f
(F) Coronal proton density weight images showing comparison of lungs in Cretm
(right). Tumors are indicated by arrows in image on left.
(G) Proton (left), pyruvate (center), and lactate (right) images acquired in Cretm-LD
around lung lesions.
(H) Spectra acquired before (two left panels) and after (two right panels) tamoxife
(I) Metabolic profiling analysis of NADH, NAD+, isocitrate, lactate, and pyruvate fro
Figure S3 for other pathway-specific metabolites).
(J) Representative caspase-3 staining of tumors from Cretm-LDH-Afl/fl;K-RAS (top
is shown on the right (mean ± SD of n = 4 mice each).
(K) Axial CT images and anterior/posterior (A/P) reconstruction from chest/lung a
LDH-Afl/fl;K-RAS treated with tamoxifen (right panel).
CAbrogation of LDH-A Results in Reactivation of
Mitochondrial Function in Cancer Cells In Vitro
In order to test the hypothesis that reduction in aerobic glycolysis
as a result of LDH-A abrogation leads to reactivation of mito-
chondrial metabolism, we performed 13C6-glucose (Glc) and
13C5,
15N2-glutamine (Gln) tracer experiments with A549 cells ex-
pressing control shRNA or LDH-A shRNA. We found by GC-MS
increased amounts of total and 13C-enriched Krebs cyclemetab-
olites (citrate, cis-aconitate, aKG, fumarate, malate, and aspar-
tate) derived from either [U-13C] glucose (Figure 6A) or [U-13C]-
glutamine, (Figure 6B). In particular, the increased synthesis of
doubly 13C-labeled (13C2- or m2-) and quadruply
13C-labeled
(13C4- or m4-) citrate from
13C6-glucose in LDH-A-suppressed
cells reflects enhanced Krebs cycle activity through the first
and second turns, respectively (cf. atom-resolved pathway
tracing in Figure 6A). Increased flux through the Krebs cycle in
these cells was also evidenced by the enhanced accumulation
of the 13C4-isotopologues of citrate, fumarate, and malate
derived from fully labeled glutamine during the first turn of the
cycle (cf. Figure 6B). In contrast, 13C enrichment of Glu was sub-
stantially attenuated (e.g., 13C5
15N-Glu or m6-Glu in Figure 6B)
by LDH-A suppression in A549 cells grown with 13C5,
15N2-Gln.
The GC-MS result was corroborated by the 1D HSQC NMR
data, as shown (Figure S6), where the abundance of the 13C-
3/13C-4-Glu and 13C-4-Glu-glutathione isotopomers was lower
in LDH-A-suppressed cells than in control cells. Even more
attenuated was the abundance of 13C-4-Gln, which could be ac-
counted for by decreased uptake and/or increased utilization of
labeled Gln through the Krebs cycle; the latter is consistent with
increased synthesis of labeled products of 13C5,
15N2-Gln oxida-
tion through the Krebs cycle (cf. Figure 6B).We further noted that
despite the reduction in levels of all 13C labeled Glu isotopo-
logues in LDH-A-suppressed cells (Figure 6B), their fractional
enrichment in these cells was comparable to that in control cells
(Figure S6). The lack of change in 13C fractional distribution
together with decreased abundance of Glu and Gln is consistent
with both reduced uptake of glutamine and increased glutami-
nolysis via the Krebs cycle induced by LDH-A knockdown.
Enhanced pyruvate carboxylation observed could represent
another anaplerotic path enhanced in LDH-A suppressed cells
perhaps to compensate for the decreased Gln uptake. OverallRAS-Induced Tumorigenesis
initiated 14 days after K-RAS induction by doxycycline diet.
corn oil (n = 6).
nd LDH-Afl/fl;K-RAS (Cretm-negative) mice (n = 4) treatedwith tamoxifen (data in
o-tailed t test).
) for LDH-A, LDH-B, and b-actin from LDH-Afl/fl;K-RAS and Cretm-LDH-Afl/fl;K-
or LDH-A, and b-actin from LDH-Afl/fl;K-RAS and Cretm-LDH-Afl/+;K-RASmice.
-LDH-Afl/fl;K-RAS mouse on doxycycline diet (left) and Cretm-LDH-Afl/fl mouse
H-Afl/fl;K-RAS mice prior to tamoxifen administration. Red outlines are drawn
n withdrawal, with signals from pyruvate (pyr) and lactate (lac) labeled at left.
m LDH-Afl/fl;K-RAS v/s. Cretm-LDH-Afl/fl;K-RAS expressed as fold change (see
panel) and LDH-Afl/fl;K-RAS (bottom panel); quantitation of caspase-3 staining
nd H&E staining of a lung section from LDH-Afl/fl;K-RAS (left panel) and Cretm-
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Figure 2. Reduction in LDH-A Levels Results in Reduced Tumorigenesis of Established Tumors in a K-RAS-Driven NSCLC Model
(A) Schematic representation of an experiment in which LDH-A knockdown was initiated 83 days after K-RAS induction by doxycycline diet.
(B and C) Tumor areas of Cretm-LDH-Afl/fl;K-RAS (n = 12), Cretm-LDH-Afl/+;K-RAS (n = 7), and LDH-Afl/fl;K-RAS (n = 6) mice that were treated with tamoxifen. Data
are represented as mean ± SD, **p, 0.01, *p < 0.05 (two-tailed t test).
(D) Representative western blot analysis of tumors (along with nonmalignant cells) from LDH-Afl/fl;K-RAS, Cretm-LDH-Afl/+;K-RAS, and Cretm-LDH-Afl/fl;K-RAS
mice for LDH-A, LDH-B, and b-actin.
(E) Axial CT images and anterior/posterior (A/P) reconstruction from chest/lung from LDH-Afl/fl;K-RASmice (left panel) and Cretm-LDH-Afl/fl;K-RASmice treated
with tamoxifen (right panel) with tumors indicated by arrows.
(F and G) Representative coronal and transverse images of lung/chest from same pre- and post-tamoxifen-treated Cretm-LDH-Afl/fl;K-RAS mice (n = 5) in
comparison to LDH-Afl/fl;K-RAS mice (n = 3).
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Figure 3. Reduction in LDH-A Levels Results in Reduced Tumorigenesis of Established Tumors inEGFR-L858R-T790M-Driven NSCLCModel
(A) Schematic representation of an experiment where LDH-A knockdown was initiated 80 days after EGFR-T790M mutation induction by doxycycline diet.
(B and C) Representative axial CT scans from pre- and post-tamoxifen tumor volume of Cretm-LDH-Afl/fl;EGFR-T790M, Cretm-LDH-Afl/+;EGFR-T790M mice.
(D) Representative western blot analysis of tumors (along with nonmalignant cells) from Cretm-LDH-Afl/+;EGFR-T790M, Cretm-LDH-Afl/fl;EGFR-T790M, and
LDH-Afl/fl;EGFR-T790M mice for LDH-A, and b-actin.
(E) Graphical representation of volumetric changes in lung volume of pre- and post-tamoxifen treated Cretm-LDH-Afl/fl;EGFR-T790M (n = 5), Cretm-LDH-
Afl/+;EGFR-T790M (n = 4), and LDH-Afl/fl;EGFR-T790M (n = 4) mice. Statistical data values are significant as tested by Dunnett’s multiple comparisons test
between all three genotypes (*WT to heterozygous; ***WT to homozygous).
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LDH-A Abrogation Impacts Tumors and CSCsdecreased synthesis of glutathiones (reduced and oxidized
forms) and increased mitochondrial metabolism are expected
to lead to increased levels of ROS.
The above findings are in line with our hypothesis that ROS
generated in response to LDH-A inhibition as a result of
increased flux of pyruvate into the mitochondria. We have also
demonstrated that these ROS are indeed mitochondrial in origin
(data not shown). The static metabolic profiles from Cretm-LDH-
Afl/fl;K-RAS or Cretm-LDH-Afl/+;K-RAS tumors (Figure 1I, 1H, and
S3) corroborated the 13C tracer analysis of increased Krebs
cycle activity as well as reduced glutathione synthesis and
increased NAD+/NADH ratio in LDH-A-suppressed cells.COurmousemodel provides a unique opportunity to investigate
metabolic reprogramming in tumors in vivo in live animals via
SIRM, using 13C6 glucose as tracer in the Cre
tm-LDH-Afl/fl;K-
RAS and LDH-Afl/fl;K-RAS mice after tamoxifen treatment. Fig-
ure 7A shows 13C abundance data of lactate and other key
metabolites in lung tumors derived from labeled glucose for
four separate experiments. Relative to the control lung tumors
(LDH-Afl/fl;K-RAS), LDH-A-suppressed lung tumor (Cretm-LDH-
Afl/fl;K-RAS) had reduced synthesis of 13C-lactate (cf. 13C-3-
Lac) (p < 0.03), which is consistent with reduced LDH-A activity.
LDH-A knockdown lung tumors also led to reduced 13C incorpo-
ration from labeled glucose into the Krebs cycle metabolites,ell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 801
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Figure 4. LDH-A Knockdown Results in Reduction of Oncogenic K-RAS-Induced Cancer Stem Cells
(Top Panel) Cancer-initiating cells within oncogenic K-RAS-expressing tumors are susceptible to LDH-A abrogration. (A) Cancer-initiating lesions from lungs of
syngeneicmice (n = 5) that were injected via tail vein with A549 cells expressing either control shRNAor LDH-A shRNA. Cancer-initiating lesions in (A) and (B) were
scored after 24 days. (B) Cancer-initiating lesions from lungs of syngeneic mice (n = 5) that were injected via tail vein with isolated tumor cells from tamoxifen-
treated Cretm-LDH-Afl/fl;K-RAS (n = 3) or LDH-Afl/fl;K-RAS (n = 2) mice. Data are expressed as ± SEM (**p < 0.01). (C) In vitro matrigel invasion assay with A549
cells expressing either control shRNA or LDH-A shRNA. Absorbance at 595 nm reflects the number of migrated cells. (D) Western immunoblotting for LDH-A and
b-actin of cells used in in vitro invasion and in vivo cancer initiation assays.
(Bottom Panel) Stem cell populations within oncogenic ras-expressing cell lines are reduced by LDH-A shRNA. (E) A549 human NSCLC cells expressing control
shRNAor two different LDH-A shRNAswere analyzed in tumorsphere formation assay, and (F) quantification of the results expressed asmean ±SD (*p < 0.05). (G)
FACS analysis of stem cell populations using CD44 and CD24 antibodies in Ras-transformed HMLE (HMLER) and shRNA-LDH-A-HMLER. (H) Tumorsphere
formation assay using tumor cells isolated from Cretm-LDH-Afl/fl;K-RAS or LDH-Afl/fl;K-RAS mice and (I) graphical quantification of the results expressed as
mean ± SD (*p < 0.05).
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Figure 5. Small Molecule LDH-A Inhibitor Reduces the Number of Ras-Induced Tumor Stem Cells
(Left Panel) (A) Chemical structure of the Compound 1. (B) Compound 1 inhibits activity of recombinant human LDH-A (IC50 = 4.8 ± 1.1 nM) and LDH-B (IC50 =
53.1 ± 0.9 nM) enzymes. The signal obtained in the absence of LDHwas set as 100% inhibition, and the signal obtained in absence of Compound 1was set as 0%
inhibition (DMSO control, not included on the graphs). Data are means ± SD of two readings, representative of six independent experiments. (C) Compound 1
inhibits lactate production in HepG2 human hepatocellular carcinoma cells. Lactate concentration was normalized to cell viability assessed by CellTiter-Fluor
assay (CTF), and the lactate/CTF ratio obtained in DMSO-treated cells was set at 100%. (D) Compound 1 (10 mM) increases ROS activity in A549 cells as
measured by DCF fluorescence (representative of two independent experiments). (E) Compound 1 (10 mM) increases oxygen consumption rate (OCR) and (F)
decreased extracellular acidification rate (ECAR) in A549 cells. XF-24 seahorse cell analyzer was used to obtain the data (means ± SD of n = 2).
(Right Panel) (G and H) Tumorsphere formation assay with A549 cells using vehicle control or 10 mM Compound 1 with graphical quantitation of the results
expressed asmean ± SD (*p < 0.05). (I) FACS analysis using CD44 andCD24 antibodies for stem cell population in ras-transformedHMLE (HMLER) treatedwith 0,
5, and 10 mMCompound 1 for 30 hr. (J) Decrease in the stem cell population in HMLER by Compound 1 treatment is specific, as it shows that CD24/44-positive
cells reappear after withdrawal of the inhibitor (Ja) plated in absence of Compound 1, (Jb) switched to media containing Compound 1 for 24 hr, and (Jc) switched
back to media without Compound 1 for an additional 24 hr. (K and L) Tumorsphere formation assay with tumor cells isolated from LDH-Afl/fl;K-RASmice treated
with DMSO or 5 mM Compound 1, with graphical quantitation of results expressed as mean ± SD (p < 0.05).
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LDH-A Abrogation Impacts Tumors and CSCsincluding Asp, Glu, Gln, succinate, and citrate, although these
effects did not reach statistical significance byWilcoxon analysis
(Figures 7 and S4A). Nonetheless, this in vivo result contrasts
with the enhanced Krebs cycle activity induced by LDH-A knock-
down in cell culture (Figure 6). Metabolic distinctions between
in vivo and in vitro systems have been observed for other tumors
(Marin-Valencia et al., 2012), which could result from tumor
microenvironmental factors absent in cell culture systems,
including interaction with stromal cells and variable nutrient sup-
ply and oxygenation. Figure 7B shows the corresponding 1HCNMR spectra for one of the tumor pairs in Figure 7A. Unlabeled
lactate (cf. H-3-Lac) and Ala (H-3-Ala) did not change, while 13C-
Lac and Ala (cf. 13Csat-3 peaks) depleted with LDH-A knock-
down. This result is consistent with reduced glycolytic flux
from glucose to lactate, while lactate production from nonglu-
cose sources may not have changed in response to LDH-A
suppression.
To test how human lung tumor tissue metabolism responded
to LDH-A attenuation, we employed ex vivo cancerous lung tis-
sues freshly resected and thinly sliced from a human NSCLCell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 803
(legend on next page)
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LDH-A Abrogation Impacts Tumors and CSCspatient (akin to ‘‘Warburg’’ slices). Similar tissue slices from
other patients maintain metabolic activity (e.g., lactate and
ATP synthesis) for up to 24 hr under our culture conditions
(data not shown). When tissue slices each were incubated
with LDH-A inhibitor (Compound 1) + 13C6-glucose or with
inhibitor + 13C5,
15N2-glutamine for 24 hr,
13C-lactate production
from labeled glucose (Figure 7C) was reduced, while that from
labeled glutamine was not (Figure 7D), which indicates a block
in the LDH-A activity by the inhibitor without altering glutamine
metabolism to lactate, corroborating with the LDH-A knockdown
mouse tumor result described above (cf. Figure 7B). However,
we noted reduced 13C incorporation from labeled glutamine
into the Krebs cycle metabolites such as succinate, citrate,
and Asp (cf. Figure 7D) in response to LDH-A inhibition, which
is consistent with the data obtained from LDH-A knockdown
mice but deviates from the in vitro cell culture result (cf. Figure 6).
DISCUSSION
This study allows us to reach a number of important conclusions:
(1) reduced LDH-A expression in the adult mouse results in
nonlethal anemia, but no other obvious toxicities; (2) reduced
LDH-A expression in highly glycolytic tumors that expresses
oncogenic K-RAS and/or EGFR L858R mutation in addition to
resistant mutation T790M results in decreased tumorigenesis
and regression of established tumors and as such may provide
therapeutic benefit; (3) both homozygous and heterozygous
deletion of LDH-A provide therapeutic efficacy; (4) LDH-A atten-
uation leads to reduced glycolytic flux in vivo, ex vivo, and
in vitro, but reactivation of the TCA cycle and anaplerosis occurs
only in vitro, implicating the important role of the microenviron-
ment in tumor metabolic reprogramming; and (5) LDH-A inhibi-
tion impacts CSCs, a population of cells not targeted by most
current therapies.
We show that loss of a single allele of LDH-A also results in
decreased tumorigenesis. Therefore, it is likely that partial inhibi-
tion by a small molecule inhibitor directed against LDH-A may
have potential antitumor activity. Of interest, we did not see
compensation by increased expression of LDH-B, though we
cannot rule out that the activity of this enzymewas not increased.
These effects of LDH-A ablation on oncogenic K-RAS-driven
tumor growth were shared by tumors carrying EGFR L858R
and T790M mutations, which render them insensitive to EGFR
inhibitors.
Our data also show that LDH-A plays a critical role in tumor
progression. Previous work from others and us has shown that
that LDH-A-suppressed cancer cell lines exhibit reduced tumor
progression in xenograft models (Fan et al., 2011a; Fantin
et al., 2006; Wang et al., 2012). These studies represent an
important milestone in validating LDH-A as a therapeutic target,Figure 6. Enhanced Utilization of Labeled Glucose and Glutamine via t
(A and B) A549 cells transduced with an empty vector (PLKO) or shRNA targetin
24 hr, as described in Experimental Procedures. The polar extracts were analyzed
with different numbers of 13C atoms) of the Krebs cycle metabolites. Also shown
tracer. Them2 (13C2) or m4 (
13C4) isotopologues derived from either tracer via the K
rectangles, while them3 (13C3) isotopologues derived from
13C6-glucose via PC ar
of two or three replicates. Solid and dashed arrows, single and multiple step reac
respectively; aKG, aketoglutarate;C, 12C;C,C, 13C in the first and second tur
Cbut they suffer from well-known artifacts of utilizing xenografts
(Frese and Tuveson, 2007). Here we circumvented these issues
by using a genetically engineered mouse (GEM) model. In this
model, we temporally ablated LDH-A expression, enabling the
investigation of LDH-A’s role in tumor regression as well as in
bystander effect on nontumor cells, which better approximates
the use of a LDH-A inhibitor in a clinical setting. LDH-A ablation
led to regression of an established tumor without serious sys-
temic toxicity.
To our knowledge, this report is the first to show that abroga-
tion of ametabolic enzyme in an established tumor model results
in reduction of the tumor burden. In fact, metabolically targeted
therapies generally delay tumor progression (Patra et al., 2013)
or are cytostatic without causing regression (Bonnet et al.,
2007; Hatzivassiliou et al., 2005).
In recent years, we have come to appreciate how substrate
utilization is dictated by oncogenic enzymes (Nilsson et al.,
2012). Based on our work, it is reasonable to hypothesize that
allRAS-transformed tumors and tumors with EFGR L858Rmuta-
tions including those that develop resistance to EGFR inhibitor
therapy may respond to LDH-A inhibition.
By using labeled tracers and SIRM analysis, we were able to
define metabolic reprogramming in lung tumor cells following
LDH-A abrogation, i.e., increased flow of carbon from both
glucose and glutamine through the Krebs cycle but reduced syn-
thesis of glutathiones from glutamine. These reprogrammed
events presumably underlie the enhanced OCR and increased
generation of ROS, previously observed by us (Xie et al., 2009).
However, the mitochondrial perturbations in cultured tumor cells
induced by LDH-A ablation were not recapitulated in vivo in our
mouse model or ex vivo in human lung tumor slices, except for
the reduced synthesis of glutathione and glutathione disulfide.
Such discrepancies between in vivo and in vitro results have
been observed in other tumor systems (e.g., glioma) (Marin-
Valencia et al., 2012) and highlight the importance of tumor
microenvironment and possibly systemic influence on tumor
metabolic reprogramming, which in turns underlies inhibition of
tumor growth or development.
Several publications described novel inhibitors of LDH-A, but
most of the inhibitors are either inactive in cell-based assays
(Dragovich et al., 2013; Kohlmann et al., 2013) or have other
issues (Le et al., 2010), as detailed in Ward et al. (2012). The
inhibitor used here (Billiard et al., 2013) is active in cell-
based assays at low mM concentrations in number of cell
lines (Figure 5; data not shown) and phenocopies the CSC re-
sults generated with either a cell line expressing LDH-A shRNA
or tumors isolated from Cretm-LDH-Afl/fl;K-RAS animals. Our
attempts to use the LDH-A inhibitor for in vivo work, either
in xenografts or GEMs, were limited by its pharmacokinetic
properties.he Krebs Cycle in LDH-A Suppressed A549 Cells
g LDH-A (LDH) were grown in 13C6-glucose (A) or
13C5,
15N2-Gln (B) tracers for
by GC-MS for the distribution of various 13C isotopologues (same metabolites
in (A) and (B) are the atom-resolved Krebs cycle tracings with each respective
rebs cycle without input from pyruvate carboxylation (PC) are denoted with red
e highlighted with green rectangles. Metabolite concentrations are means ± SD
tions; single- and double-headed arrows, irreversible and reversible reactions,
n without PC input;C, 13C with PC input.
ell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 805
Figure 7. LDH-A Suppression in Cretm-LDH-Afl/fl;K-RAS Mouse Lung Tumors and Its Pharmacological Inhibition in Primary Human Lung
Tumor Tissue Blocked Glucose Oxidation via Glycolysis without Activating the Krebs Cycle
(Top panel) Four each LDH-Afl/fl;K-RAS (Ctl) and Cretm-LDH-Afl/fl;K-RAS (LDH-A KO) mice were tail vein injected with 20 mg of 13C6-glucose in sterile PBS three
times at 15 min intervals prior to dissection for lung tumor tissues (one of the LDH-A KO mice had insufficient tissue for metabolite analysis). Polar metabolites
were extracted from frozen pulverized tissue powder and analyzed by 1D 1H and 1H-{13C} HSQC NMR as described for Warburg slices in Experimental Pro-
cedures. (A) HSQC spectra for one pair of control versus LDH-A knockdown mouse tumors, where the intensity of each assigned metabolite 1H signal reflect
the 13C abundance of the attached carbon. Also shown is the average content (mean ± SE) of selected 13C-labeled glycolytic and Krebs cycle metabolites
(as 13C mmole/g protein) obtained from theHSQCdata (four each for Ctl and LDH-AKO). 13C-metaboliteswere quantified from the peak areas of respective HSQC
resonances using the 13C-3-Lac resonance as a calibrator. The 13C abundance of 3-Lac was obtained from the 1H NMR spectra as in (B) calibrated against the
DSS standard. Lac, lactate; NMe-PCholine, N-methyl protons of phosphocholine; Glc, glucose; G6P, glucose-6-phosphate; UDP-GlcNAc, UDP-N-acetylglu-
cosamine; UXP, uracil nucleotides; AXP, adenine nucleotides. LDH-A KO induced reduced production of 13C-lactate from 13C6-glucose, which is consistent with
decreased glycolytic flow, while it also elicited attenuated synthesis of 13C-Ala, 13C-Glu, 13C-succinate, 13C-citrate, and 13C-Asp, but this attenuation did not
reach statistical significance (cf. Figure S4). Suffice to say, Krebs cycle activity was not activated by LDH-A suppression. (B) 1H spectrum of one of the five pairs of
tumors. 13Csat-3-Lac, the
13C satellite peaks of the H3 of lactate, the pattern of which indicates fully 13C-labeled lactate; GSH+GSSG, reduced and oxidized
glutathiones. Reduced production of 13C-lactate and 13C-Ala with little changes in the levels of the unlabeled counterparts is evident.
(Bottom panel) Two tissue slices were procured from one resected human NSCLC tumor, each treated with 13C6-glucose and
13C5,
15N2-glutamine, and pro-
cessed as described in Experimental Procedures. (C) and (D) display, respectively, the 1D 1H-{13C} HSQC spectra of 13C6-glucose and
13C5,
15N2-glutamine-
treated slices with or without LDH-A inhibitor (10 mM Compound 1). Also shown is the content of selected 13C-labeled glycolytic and Krebs cycle metabolites
(as 13C mmole/g protein, determined as in A) obtained from the HSQC data. LDH-A inhibitor-induced reduction in 13C-lactate production from 13C6-glucose is
evident in (C), while decreased synthesis of Krebs cyclemetabolites (succinate, citrate, and Asp) and glutathiones from 13C5,
15N2-glutamine in response to LDH-A
inhibition are shown in (D). Also clear from (D) is the lack of change in 13C-lactate production from 13C5,
15N2-glutamine with LDH-A inhibition.
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LDH-A Abrogation Impacts Tumors and CSCsAlthough it has been speculated that CSCs reside in hypoxic
niche (Lock et al., 2013; Zhang et al., 2012), relatively little is
known about the metabolic properties of these cells. We show
that reduced LDH-A expression impacts CSCs using estab-
lished in vivo, in vitro, and ex vivo assays. Some of these findings
were further validated with our LDH-A-specific inhibitor. As in the
case for non-CSCs, these effects are likely to be mediated via806 Cell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc.perturbations to the mitochondrial Krebs cycle, as CSCs pro-
duce more ROS compared to non-stem counterpart. The ROS
production by CSCs was further enhanced by LDH-A suppres-
sion (Figures S7A and S7B). Thus, CSCs could be more vulner-
able to LDH-A blockade due to the overall lower capacity of their
Krebs cycle (with limitation at the succinate dehydrogenase or
SDH step of Complex II), despite a low glycolytic capacity,
Cell Metabolism
LDH-A Abrogation Impacts Tumors and CSCsrelative to the non-CSCs (cf. Figure S7C). Complex II is prone
to producing superoxide, and its overburden in LDH-A sup-
pressed CSCs may account for the observed excess production
of ROS. The Krebs cycle together with the electron transport
chain would be less able to oxidize the excess pyruvate or
regenerate NAD+ in the cytoplasm via the malate/Asp shuttle
to sustain glycolysis. The finding that LDH-A inhibition/ablation
impacts CSCs, a population of cells not targeted by a vast
majority of current therapies, sets the stage for preclinical com-
binatorial trials with currently approved therapies for NSCLC.
Finally, in the past few years, there has been rising excitement
in exploring metabolic enzymes as novel targets for cancer
therapy. These new strategies promise to circumvent the long-
standing limitations of targeting tumor suppressors or onco-
genes with the large number of permutations of mutations that
tumors can adopt to evade therapies. Targeting metabolic pro-
cesses or the ‘‘end game’’ for tumorigenic mutations offers
exciting clinical opportunities.
EXPERIMENTAL PROCEDURES
Cells and Cell Culture
A549 and HepG2 cells were purchased from the American Type Culture
Collection and maintained in Ham’s F-12 medium (Mediatech, Inc) with 10%
FCS and penicillin/streptomycin (P/S). Immortalized human breast epithelial
cells (HMLE) were gifts from Dr. Robert Weinberg (Whitehead Institute). All
cell lines were grown as described earlier (Hanai et al., 2013).
Flow Cytometry Analysis and Fluorescence-Activated Cell Sorting
HMLER cells were fluorescence-activated cell sorting (FACS) sorted into
stem cell population (S, CD44 high and CD24 low) and non-stem cell
population (NS, CD44 low and CD24 high) as described earlier (Hanai et al.,
2013).
Tumorsphere Formation Assay
Single cells were plated in 6-well ultralow attachment plates (Corning) at
a density of 20,000 viable cells/ml and were processed as described
earlier (Hanai et al., 2013). Two-tailed t test was used to evaluate the statis-
tical significance of the results. All values are expressed as mean ± SE for
this assay.
Oxygen Consumption and PPR Analysis by XF24 Seahorse Platform
The XF24 Extracellular Flux analyzer (Seahorse Biosciences, Billerica,MA) was
used to measure oxygen consumption (OCR) and extracellular acidification
rate (ECAR). Results were expressed as percent ECAR or percent OCR.
Steady-State Metabolic Analysis
Metabolic analysis was performed by BIDMC mass spectrometry core
facility. Sample preparation was done according to a procedure developed
by the core. Data were analyzed by the web server software located at
http://www.metaboanalyst.ca/MetaboAnalyst/faces/Home.jsp. The normal-
ized data were plotted using PRISM software.
Tamoxifen Treatment
All animal studies and procedures were approved by BIDMC Institutional
Animal Care and Use Committee and were conducted in accordance with
the BIDMC policy on the care, welfare, and treatment of laboratory animals.
As described in the results section, the mice were treated with tamoxifen
(10mgml1 in corn oil) or corn oil (only for Figure 3B) (Sigma) by intraperitoneal
injection. A total of 76 mice were used in all the experiments.
Doxycycline Treatment
Doxycycline chow (Harlan, Teklad) was used as described previously (Fisher
et al., 2001).CPCR Genotype and Western Blot Analysis
PCR primers developed by SANGER were used to detect modified LDH-A
allele. Western blot analysis was carried out to further validate loss of LDH-A
protein.
Statistical Analysis
Means, medians, Welch two-tailed t tests, Wilcoxon rank sum test, and
descriptive statistics were calculated as appropriate using Prism software
package or Kaleidagraph (Synergy Software). The error bars represented in
each figure are mean ± SD or ± SEM, and appropriate analysis is indicated
in figure legends. p < 0.05 was considered statistically significant.
Tumor-Initiating Cell Assay
Athymic mice were injected via tail vein with A549 cells (104 in 100 ml) that were
expressing either control shRNA or LDH-A shRNA. For TIC assay in syngenic
mice, tumor cells (104 in 100 ml) isolated from either corn oil or tamoxifen-
treated Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice were injected
via tail vein. Animals were monitored for 21 days postinjection and euthanized
as per established guidelines. Total number of animals used for these assays
was 20.
Tumor Area Measuring and Lung Metastasis Assay
Lung organs from two mice bearing RAS-driven tumor were removed and
washed three times with PBS. Formalin-fixed, paraffin-embedded mouse
lung tissue sections were prepared at 5 mm. For each slide, two or three
sections cut from different distances were collected and stained by H&E
method. H&E-stained slides were scanned, and tumor area was quantified
with Image J (NIH software).
LDH Enzymatic and Lactate Production Assay
These assays were performed as described previously (Billiard et al., 2013).
Hyperpolarizer and Proton Imaging
All imaging procedures were approved by our Institutional Animal Care and
Use Committee (IACUC) using methods described previously (Seth et al.,
2011). 13C magnetic resonance spectroscopic imaging (MRSI) was performed
using two-dimensional chemical shift imaging (2D CSI) as described (Kohler
et al., 2007).
Micro CT Studies
Animals were anesthetized with 2% isoflurane/balance O2. Imaging was per-
formed using the CT component of a NanoPET/CT (Bioscan, Washington, DC)
scanner, and image analysis was performed using VivoQuant software
(inviCRO, Boston, MA) using a Hounsfield Unit windowing technique, normal-
ized for all scans. Volumetric segmentation was performed using a neighbor-
hood threshold.
SIRM Analysis
SIRM studies with 13C-enriched tracers were carried out as previously
described for both cells in culture and in mice (Fan et al., 2011b, 2012). Metab-
olites were analyzed byGC-MS and NMR according to standardized protocols
as previously described (Lane et al., 2008), using in-house databases of stan-
dards for identification (Fan and Lane, 2008). Isotopomer distributions and
fractional enrichments were calculated as previously described (Lane et al.,
2008).
Warburg Slices
‘‘Warburg slices’’ are thin slices (<1 mm thick) of tissue, two of which were
immediately cut from a freshly resected human NSCLC tumor using a
Weck microtome and were maintained in DMEM medium supplemented
with 10% FBS, 13 penicillin, and streptomycin plus 0.2% 13C6-glucose
and 2 mM glutamine or 0.2% glucose and 2 mM 13C5,
15N2-glutamine under
5% CO2 at 37
C for 24 hr without or with 20 mM Compound 1. The tissues
were harvested by rinsing briefly in cold PBS, blotted dry, and weighed
before being flash frozen in liquid N2. Metabolites were extracted and
analyzed by 1H{13C} HSQC NMR as described previously (Fan et al.,
2011b, 2012).ell Metabolism 19, 795–809, May 6, 2014 ª2014 Elsevier Inc. 807
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